Brokerages Expect ESSA Pharma Inc (EPIX) Will Post Earnings of -$0.44 Per Share

Share on StockTwits

Wall Street brokerages predict that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will post earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.83) in the same quarter last year, which suggests a positive year over year growth rate of 47%. The company is expected to issue its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that ESSA Pharma will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.84) to ($1.11). For the next financial year, analysts anticipate that the firm will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.49) to ($1.11). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for ESSA Pharma.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings results on Thursday, February 7th. The company reported ($0.42) earnings per share for the quarter.

Separately, HC Wainwright reiterated a “buy” rating on shares of ESSA Pharma in a research report on Friday, February 15th.

Shares of EPIX stock opened at $2.38 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.54 and a quick ratio of 3.54. The company has a market cap of $15.02 million, a P/E ratio of -0.93 and a beta of 2.55. ESSA Pharma has a twelve month low of $1.87 and a twelve month high of $5.83.

ESSA Pharma Company Profile

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

See Also: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.